Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Surrogate markers of antitumor responses: In vitro activation of T cells by autologous tumor peptides
Autore:
Zier, K; Maddux, JM; Johnson, K; Sung, M; Mandeli, J; Eisenbach, L; Schwartz, M;
Indirizzi:
CUNY Mt Sinai Sch Med, Immunobiol Ctr, New York, NY 10029 USA CUNY Mt Sinai Sch Med New York NY USA 10029 l Ctr, New York, NY 10029 USA CUNY Mt Sinai Sch Med, Div Clin Immunol, New York, NY 10029 USA CUNY Mt Sinai Sch Med New York NY USA 10029 munol, New York, NY 10029 USA CUNY Mt Sinai Sch Med, Div Med Oncol, New York, NY 10029 USA CUNY Mt SinaiSch Med New York NY USA 10029 Oncol, New York, NY 10029 USA CUNY Mt Sinai Sch Med, Inst Gene Therapy, New York, NY 10029 USA CUNY Mt Sinai Sch Med New York NY USA 10029 erapy, New York, NY 10029 USA CUNY Mt Sinai Sch Med, Dept Biomath Sci, New York, NY 10029 USA CUNY Mt Sinai Sch Med New York NY USA 10029 h Sci, New York, NY 10029 USA CUNY Mt Sinai Sch Med, Dept Surg, New York, NY 10029 USA CUNY Mt Sinai SchMed New York NY USA 10029 Surg, New York, NY 10029 USA Weizmann Inst Sci, Dept Cell Biol, IL-76100 Rehovot, Israel Weizmann Inst Sci Rehovot Israel IL-76100 Biol, IL-76100 Rehovot, Israel
Titolo Testata:
CLINICAL CANCER RESEARCH
fascicolo: 3, volume: 7, anno: 2001, supplemento:, S
pagine: 818S - 821S
SICI:
1078-0432(200103)7:3<818S:SMOARI>2.0.ZU;2-Y
Fonte:
ISI
Lingua:
ENG
Soggetto:
GAMMA-ELISPOT-ASSAY; PERIPHERAL-BLOOD; SECRETING CELLS; LYMPHOCYTES; ANTIGENS; MELANOMA; QUANTIFICATION; VACCINES;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
21
Recensione:
Indirizzi per estratti:
Indirizzo: Zier, K CUNY Mt Sinai Sch Med, Immunobiol Ctr, Box 1089,1425 Madison Ave, New York, NY 10029 USA CUNY Mt Sinai Sch Med Box 1089,1425 Madison Ave New York NY USA 10029
Citazione:
K. Zier et al., "Surrogate markers of antitumor responses: In vitro activation of T cells by autologous tumor peptides", CLIN CANC R, 7(3), 2001, pp. 818S-821S

Abstract

The increasing ability to augment antitumor immunity in model:systems has led to increased numbers of clinical trials. However, progress in detectingimmune responses by patients against autologous tumors has been slow, Although a considerable number of tumor antigens, as well as peptides derived from them, and the MHC determinants together with which they are presented have been identified for melanoma, this is not so for the majority of solid tumors. Furthermore, tumor cells themselves are poor stimulators of immunity. Thus, approaches that do not depend upon defined antigens or using tumorcells as stimulators would be desirable. To attempt to measure immune responses in these situations, we tested whether total peptides, prepared from autologous tumor tissue, stimulated cytokine release by T cells. Peripheralblood mononuclear cells (PBMCs) were mixed with antigen-presenting cells (APCs), pulsed with tumor peptides, and tested in the ELISPOT assay for IFN-gamma secretion. Few spots were obtained when PBMCs were cultured with unpulsed APCs or in wells with peptide-pulsed APC alone. In contrast, a strong response was seen when PBMCs were cultured with APCs that had been pulsed with autologous total tumor peptides, This system should help to identify those immunotherapeutic approaches that induce responses against tumor cells in vivo. Because different cytokine profiles are associated with distinct arms of the immune response, testing in the ELISPOT assay may also help us understand the mechanisms responsible.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 23/01/20 alle ore 03:25:48